The US Food and Drug Administration (FDA) approved a new use for aflibercept (Eyelea/Regeneron). The FDA ruled today that the drug may be used to treat diabetic retinopathy in patients with diabetic macular edema (DME). The drug is already in use for treating age-related wet macular degeneration.
It is the second drug approved this year to treat DME. In February, the FDA approved ranibizumab (Lucentis/Genentech) for that use.